Resveratrol as a Novel Therapeutic Agent for Treating Duchenne Muscular Dystrophy

Resveratrol as a Novel Therapeutic Agent for Treating Duchenne Muscular Dystrophy

Show other versions (1)

Duchenne Muscular Dystrophy (DMD) is an x-linked neuromuscular disease that is caused by an absence of dystrophin protein, rendering skeletal muscle more susceptible to contraction-induced damage. One therapeutic strategy focuses on increasing the expression of endogenous utrophin A, a dystrophin h...

Full description

Bibliographic Details
Main Author:	Burt, Matthew
Other Authors:	Jasmin, Bernard
Language:	en
Published:	Université d'Ottawa / University of Ottawa 2013
Subjects:	resveratrol skeletal muscle utrophin dystrophin mdx duchenne muscular dystropy slow oxidative myogenic program sirt1 pgc-1 alpha
Online Access:	http://hdl.handle.net/10393/26273 http://dx.doi.org/10.20381/ruor-3321

Similar Items

Resveratrol as a Novel Therapeutic Agent for Treating Duchenne Muscular Dystrophy
by: Burt, Matthew
Published: (2013)

Combinatorial Utrophin A Activation in Muscle as a Therapeutic Strategy to Treat Duchenne Muscular Dystrophy
by: Ahmed, Aatika
Published: (2015)

AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy
by: Michel Abou‐Samra, et al.
Published: (2020-04-01)

Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy
by: Sharon Mordechay, et al.
Published: (2021-06-01)

Importância do camundongo mdx na fisiopatologia da distrofia muscular de Duchenne The importance of mdx mouse in the pathophysiology of Duchenne's muscular distrophy
by: Sandra Lopes Seixas, et al.
Published: (1997-09-01)

Arginine butyrate per os protects mdx mice against cardiomyopathy, kyphosis and changes in axonal excitability
by: Sara Vianello, et al.
Published: (2014-11-01)

Natural history of Duchenne muscular dystrophy
by: Qing KE, et al.
Published: (2015-05-01)

Dystrophin Is Required for the Proper Timing in Retinal Histogenesis: A Thorough Investigation on the mdx Mouse Model of Duchenne Muscular Dystrophy
by: Irene Persiconi, et al.
Published: (2020-08-01)

Determining the Contribution of Utrophin A Versus Other Components of the Slow, Oxidative Phenotype in the Beneficial Adaptations of Dystrophic Muscle Fibers Following AMPK Activation
by: Al-Rewashdy, Hasanen
Published: (2014)

Exploring Dystrophin-Mediated Control of Neural Stem Cell Fate Associated with Intellectual Disability In Duchenne Muscular Dystrophy Patients
by: Thompson, Shannon
Published: (2018)

Immune Response Markers are Prevalent in the mRNA Expression Profile of Maturing Dystrophic Murine Skeletal Muscle
by: Gainer, Thomas Gregory
Published: (2014)

Efficacy of Prednisolone in Generated Myotubes Derived From Fibroblasts of Duchenne Muscular Dystrophy Patients
by: Tsubasa Kameyama, et al.
Published: (2018-12-01)

High Throughput Screening in Duchenne Muscular Dystrophy: From Drug Discovery to Functional Genomics
by: Thomas J.J. Gintjee, et al.
Published: (2014-11-01)

Skeletal muscle homeostasis in Duchenne muscular dystrophy: modulating autophagy as a promising therapeutic strategy
by: Clara eDe Palma, et al.
Published: (2014-07-01)

Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies
by: Elisabeth Le Rumeur
Published: (2015-07-01)

Molecular mechanism of sphingosine-1-phosphate action in Duchenne muscular dystrophy
by: Diem-Hang Nguyen-Tran, et al.
Published: (2014-01-01)

l-arginine improves dystrophic phenotype in mdx mice
by: Vincent Voisin, et al.
Published: (2005-10-01)

Language Delay in Duchenne’s Muscular Dystrophy
by: J Gordon Millichap
Published: (2007-06-01)

Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update
by: Chengmei Sun, et al.
Published: (2020-07-01)

Progress study of the cardiac damage in Duchenne muscular dystrophy
by: Yao ZHANG, et al.
Published: (2013-05-01)

Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture
by: Keryn G. Woodman, et al.
Published: (2016-11-01)

Myelination is delayed during postnatal brain development in the mdx mouse model of Duchenne muscular dystrophy
by: Azeez Aranmolate, et al.
Published: (2017-08-01)

Fatores potencialmente envolvidos na proteção das fibras musculares em músculos intrínsecos da laringe de camundongos mdx
by: Ferretti, Renato, 1982-
Published: (2012)

Resveratrol Promotes Hypertrophy in Wildtype Skeletal Muscle and Reduces Muscle Necrosis and Gene Expression of Inflammatory Markers in <i>Mdx</i> Mice
by: Keryn G. Woodman, et al.
Published: (2021-02-01)

Intellectual Ability in the Duchenne Muscular Dystrophy and Dystrophin Gene Mutation Location
by: Rasic Milic V., et al.
Published: (2014-12-01)

Duchenne muscular dystrophy: alpha-dystroglycan immunoexpression in skeletal muscle and cognitive performance Distrofia muscular de Duchenne: imunoexpressão da alfa-distroglicana em musculatura esquelética e performance cognitiva
by: Conceição Campanario da Silva Pereira, et al.
Published: (2005-12-01)

"Molecular Analysis of Iranian Patients with Duchenne/Becker Muscular Dystrophies"
by: S Kheradmand kia, et al.
Published: (2003-09-01)

"Molecular Analysis of Iranian Patients with Duchenne/Becker Muscular Dystrophies"
by: S Kheradmand kia, et al.
Published: (2003-09-01)

Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy
by: Cara A. Timpani, et al.
Published: (2017-05-01)

State-of-the-art Advances in Duchenne Muscular Dystrophy
by: Henriette Van Ruiten, et al.
Published: (2017-03-01)

Brazilian consensus on Duchenne muscular dystrophy. Part 1: diagnosis, steroid therapy and perspectives
by: Alexandra P. Q. C. Araujo, et al.

A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys
by: Michael St. Andre, et al.
Published: (2017-11-01)

Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
by: Fernanda Fortunato, et al.
Published: (2021-02-01)

Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy
by: Gonzalo Cordova, et al.
Published: (2018-04-01)

Expression of dystrophin-glycoprotein complex at the skeletal muscle sarcolemma in Duchenne muscular dystrophy
by: Lei ZHAO, et al.
Published: (2015-06-01)

Altered visual processing in the mdx52 mouse model of Duchenne muscular dystrophy
by: Mirella Telles Salgueiro Barboni, et al.
Published: (2021-05-01)

Genome Editing-Mediated Utrophin Upregulation in Duchenne Muscular Dystrophy Stem Cells
by: Kasturi Sengupta, et al.
Published: (2020-12-01)

Duchenne/Becker muscular dystrophy: A report on clinical, biochemical, and genetic study in Gujarat population, India
by: Mandava V Rao, et al.
Published: (2014-01-01)

CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy
by: Kenji Rowel Q. Lim, et al.
Published: (2020-03-01)

Exploring fibrosis in muscular dystrophy through modulation of the TGF-beta pathway
by: St. Andre, Michael William
Published: (2021)